Aspen Neuroscience, Inc. Form 424B4 — Oct 30, 2026
Aspen Neuroscience priced its IPO at $15.00 per share, selling 9,375,000 shares for gross proceeds of $140.6 million (about $125.8 million net), with shares set to trade on Nasdaq under symbol ASPE beginning around November 2, 2026. Underwriters hold a 30-day option on up to 1,406,250 additional shares. The company is a clinical-stage regenerative medicine biotech developing autologous iPSC-derived cell therapies, led by sasineprocel for Parkinson's disease. Open-label Phase 1/2a ASPIRO data showed sustained motor and quality-of-life improvements above clinically meaningful benchmarks, and the company plans Phase 3 initiation with dosing in the second half of 2027.
Key figures
- Greenshoe
- 1406250
- Gross Proceeds
- 140625000
- Offering Price
- 15
- Shares Offered
- 9375000
- Runway
- into the second half of 2028
- Net Proceeds
- $125.8 million (or ~$145.4 million if greenshoe exercised in full)
- Net Loss FY2024
- $48.6 million
- Net Loss FY2025
- $62.1 million
- Reverse Split Ratio
- 1-for-9.8821
- Accumulated Deficit
- $264.9 million
- Net Loss Six Months2026
- $36.5 million
- Pro Forma Cash Jun30 2026
- $198.2 million
- Total Raised Since Inception
- approximately $347 million
- Underwriting Discount Per Share
- 1.05
- Shares Outstanding Post Offering
- 29078600
- Cash And Marketable Securities Jun30 2026
- $72.4 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.